GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Goodbody Health Ltd (OTCPK:GDBYF) » Definitions » Peter Lynch Fair Value

Goodbody Health (Goodbody Health) Peter Lynch Fair Value : N/A (As of May. 04, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Goodbody Health Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Goodbody Health's Peter Lynch Fair Value or its related term are showing as below:



GDBYF's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.43
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Goodbody Health Peter Lynch Fair Value Historical Data

The historical data trend for Goodbody Health's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Goodbody Health Peter Lynch Fair Value Chart

Goodbody Health Annual Data
Trend Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Dec21
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Goodbody Health Quarterly Data
Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Goodbody Health's Peter Lynch Fair Value

For the Drug Manufacturers - Specialty & Generic subindustry, Goodbody Health's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Goodbody Health's Price-to-Peter-Lynch-Fair-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Goodbody Health's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Goodbody Health's Price-to-Peter-Lynch-Fair-Value falls into.



Goodbody Health Peter Lynch Fair Value Calculation

Goodbody Health's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0.063
=N/A

Goodbody Health's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Goodbody Health  (OTCPK:GDBYF) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Goodbody Health's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.0003/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Goodbody Health Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Goodbody Health's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Goodbody Health (Goodbody Health) Business Description

Traded in Other Exchanges
N/A
Address
Stubbs Lane, Beckington Frome, The Blue Building, Somerset, GBR, BA11 6TE
Goodbody Health Ltd is a wellness company operating in both COVID testing in the United Kingdom and as a vertically integrated cannabinoid CBD company that operates in the United Kingdom and the European Union. It has interests in COVID testing clinics, CBD extraction, wholesale bulk isolate, and distillate sales, retail CBD and white label sales, cannabinoid laboratory testing, and medicinal cannabis research programs.

Goodbody Health (Goodbody Health) Headlines